MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
7.85
+0.54
+7.39%
After Hours: 7.95 +0.1 +1.27% 19:59 12/31 EST
OPEN
7.89
PREV CLOSE
7.31
HIGH
8.22
LOW
7.55
VOLUME
5.33M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
3.140
MARKET CAP
1.30B
P/E (TTM)
-75.9188
1D
5D
1M
3M
1Y
5Y
1D
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
The Motley Fool · 19h ago
Weekly Report: what happened at XERS last week (1222-1226)?
Weekly Report · 12/29/2025 09:28
Have Xeris Biopharma Holdings Insiders Been Selling Stock?
Simply Wall St · 12/22/2025 10:18
Weekly Report: what happened at XERS last week (1215-1219)?
Weekly Report · 12/22/2025 09:28
Xeris Biopharma (XERS): Assessing Valuation as Investors Back Its Shift to Profitable Specialty Pharma
Simply Wall St · 12/20/2025 23:25
Xeris Pharmaceuticals Director Makes Major Insider Move
TipRanks · 12/20/2025 02:04
Director John Johnson Reports Sale of Xeris Biopharma Holdings Inc. Common Shares
Reuters · 12/19/2025 22:18
How Xeris Biopharma’s Shift Toward Profitability and Pipeline Maturity Will Impact Xeris (XERS) Investors
Simply Wall St · 12/19/2025 08:20
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.